Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

An Assessment of Patients Factors Effect on Prescriber Adherence to Ischemic Stroke Secondary Prevention Guidelines

Author(s): Majdi Al Qawasmeh, Ahmed Alhusban*, Firas Alfwaress and Khalid El-Salem

Volume 16, Issue 1, 2021

Published on: 23 January, 2020

Page: [97 - 102] Pages: 6

DOI: 10.2174/1574884715666200123145350

Abstract

Background: Stroke is the leading cause of long-term disability worldwide. Stroke recurrence is a major health problem with devastating consequences. Adherence to secondary prevention guidelines reduced stroke recurrence. Data regarding prescriptions adherence to secondary prevention guidelines in the Middle East and North Africa is lacking.

Objectives: The aim of this study is to assess the degree of physician adherence to ASA guidelines and the patient specific factors that affect their prescribing patterns in a major teaching hospital in Jordan.

Methods: Ischemic stroke patients referring to King Abdullah University Hospital were approached and offered a description of the study to obtain their informed consent. After getting the informed consent, their prescription at the time of discharge was evaluated for adherence to secondary prevention guidelines and classified into adherent and non-adherent based on a composite score that included each of the guidelines which indicated therapeutic classes. Odds ratio for adherence and their 95%confidence intervals were calculated and adherence to specific therapeutics classes was evaluated.

Results: Two hundred and seventy-five patients were included in this evaluation. Less than 50% of the patients received guideline’s adherent prescriptions. Patients with hypertension and hyperlipidemia were associated with a lower probability were prescribed a guidelines adherent regimen (OR 0.485, 0.0.225, respectively). ACEI/ARBs combination with thiazides was prescribed to about 11.52% of the patients.

Conclusion: Adherence to stroke secondary prevention guidelines was suboptimal especially in the antihypertensive prescription component. Further assessments and evaluations are required to improve guidelines adherence.

Keywords: Guidelines adherence, hypertension, prescribers' attitude, patient factors, secondary prevention, stroke.

« Previous Next »
Graphical Abstract

[1]
Benjamin EJ, Muntner P, Alonso A, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 2019; 139(10): e56-e528.
[http://dx.doi.org/10.1161/CIR.0000000000000659] [PMID: 30700139]
[2]
Kernan WN, Ovbiagele B, Black HR, et al. American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45(7): 2160-236.
[http://dx.doi.org/10.1161/STR.0000000000000024] [PMID: 24788967]
[3]
Talelli P, Greenwood RJ. Recurrent stroke: Where do we stand with the secondary prevention of noncardioembolic ischaemic strokes? Ther Adv Cardiovasc Dis 2008; 2(5): 387-405.
[http://dx.doi.org/10.1177/1753944708093411] [PMID: 19124436]
[4]
Ahmed N, Steiner T, Caso V, Wahlgren N. ESO-KSU session participants. Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13-15 November 2016. Eur Stroke J 2017; 2(2): 95-102.
[http://dx.doi.org/10.1177/2396987317699144] [PMID: 29900406]
[5]
Wein T, Lindsay MP, Côté R, et al. Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. Int J Stroke 2018; 13(4): 420-43.
[6]
Degli Esposti L, Saragoni S, Batacchi P, et al. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: Results from an administrative database analysis. Clin Ther 2012; 34(1): 190-9.
[http://dx.doi.org/10.1016/j.clinthera.2011.12.011] [PMID: 22284998]
[7]
Ma R, Wang C, Zhao X, et al. A survey on compliance with secondary stroke prevention guidelines and follow up for the inpatients with atherosclerotic cerebral infarction/transient ischemic attack. Neurol Res 2008; 30(4): 383-8.
[http://dx.doi.org/10.1179/174313208X300404] [PMID: 18544256]
[8]
Miyazawa K, Li YG, Rashed WA, et al. Secondary stroke prevention and guideline adherent antithrombotic treatment in patients with atrial fibrillation: Insights from the Gulf Survey of Atrial Fibrillation Events (Gulf SAFE). Int J Cardiol 2019; 274: 126-31.
[http://dx.doi.org/10.1016/j.ijcard.2018.07.120] [PMID: 30064925]
[9]
Shaya FT, El Khoury AC, Mullins CD, et al. Drug therapy persistence and stroke recurrence. Am J Manag Care 2006; 12(6): 313-9.
[PMID: 16756450]
[10]
Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373(9678): 1849-60.
[http://dx.doi.org/10.1016/S0140-6736(09)60503-1]] [PMID: 19482214]
[11]
Asberg S, Henriksson KM, Farahmand B, et al. Ischemic stroke and secondary prevention in clinical practice: A cohort study of 14,529 patients in the Swedish Stroke Register. Stroke 2010; 41(7): 1338-42.
[http://dx.doi.org/10.1161/STROKEAHA.110.580209]] [PMID: 20522818]
[12]
Group PC. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-41.
[http://dx.doi.org/10.1016/S0140-6736(01)06178-5] [PMID: 11589932]
[13]
Fujino T, Hasebe N, Kikuchi K. Evidence-based usefulness of Ca antagonists and ACEIs and ARBs for the primary and secondary prevention of major cardiovascular and renal events in patients with hypertension. Clin Calcium 2005; 15(10): 1695-708.
[PMID: 16199917]
[14]
Lindholm LH, Ibsen H, Dahlöf B, et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359(9311): 1004-10.
[http://dx.doi.org/10.1016/S0140-6736(02)08090-X] [PMID: 11937179]
[15]
Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45(5): 712-9.
[http://dx.doi.org/10.1016/j.jacc.2004.10.068] [PMID: 15734615]
[16]
Van MW. Prevention of major cardiovascular events with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker early or late after stroke. J Hypertens Suppl 2009; 27(2): S26-31.
[http://dx.doi.org/10.1097/01.hjh.0000354517.82698.51] [PMID: 19491619]
[17]
Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388(10059): 2532-61.
[http://dx.doi.org/10.1016/S0140-6736(16)31357-5] [PMID: 27616593]
[18]
Nakamura M, Fukukawa T, Kitagawa K, et al. for J-STARS collaborators. Ten-year standardization of lipids and high-sensitivity C-reactive protein in a randomized controlled trial to assess the effects of statins on secondary stroke prevention: Japan Statin Treatment against Recurrent Stroke. Ann Clin Biochem 2018; 55(1): 128-35.
[http://dx.doi.org/10.1177/0004563217693651] [PMID: 28135841]
[19]
Chi NF, Wen CP, Liu CH, et al. Taiwan Stroke Registry Investigators. Comparison between aspirin and clopidogrel in secondary stroke prevention based on real-world data. J Am Heart Assoc 2018; 7(19)e009856
[http://dx.doi.org/10.1161/JAHA.118.009856]] [PMID: 30371321]
[20]
Committee CS. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996; 348(9038): 1329-39.
[http://dx.doi.org/10.1016/S0140-6736(96)09457-3] [PMID: 8918275]
[21]
Geeganage CM, Diener HC, Algra A, et al. Acute antiplatelet stroke trialists collaboration. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: Systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43(4): 1058-66.
[http://dx.doi.org/10.1161/STROKEAHA.111.637686] [PMID: 22282894]
[22]
Hao Q, Tampi M, O’Donnell M, Foroutan F, Siemieniuk RA, Guyatt G. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: Systematic review and meta-analysis. BMJ 2018; 363: k5108.
[http://dx.doi.org/10.1136/bmj.k5108] [PMID: 30563866]
[23]
Zhang Q, Wang C, Zheng M, et al. Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: A systematic review and meta-analysis. Cerebrovasc Dis 2015; 39(1): 13-22.
[http://dx.doi.org/10.1159/000369778]] [PMID: 25547900]

Rights & Permissions Print Cite
Article Metrics
22
2
© 2024 Bentham Science Publishers | Privacy Policy